9 September 2019
Roes is a biostatistician with extensive experience in statistical applications, research and education. He is a noted expert in the field of clinical studies, methodology and quality of clinical research. His research mainly concentrates on innovative designs and the analysis of clinical research for rare disorders, a focus that fits well with the more individual patient-oriented treatment.
Radboud university medical center
At Radboud university medical center, Prof. Roes and his team will further expand the contribution of biostatistics to research. The combination of innovative designs for (clinical) research and the increasing possibilities offered by prediction and modelling offer the opportunity to evaluate new treatments and techniques more efficiently and thus bring them to the patient more quickly.
Educating students about statistics and biostatistics is extremely important to a number of programmes. Roes will participate in that effort by focusing on the innovations that are taking place in that field, including design and the increasing availability of large data sets.
About Kit Roes
Kit Roes (Nijmegen, 1961) studied mathematics at Radboud University. After graduation, he went to work as an adviser at Philips. He gained more than 10 years’ experience in quality improvement at various companies and in various settings. He earned a PhD in a related context, focusing on new statistical methods for process control.
Biostatistics became his focus when he began working at Organon. He now has more than 15 years’ experience in clinical and non-clinical research into drug development and he has contributed to the development and registration of new drugs in various therapeutic areas. He has been a professor at UMC Utrecht for the past 10 years, where he initiated and led the EU project Asterix about methodologies for clinical studies of rare diseases.
Prof. Roes is chair of the Methodology work group at the College ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board) and a member of the Biostatistics Working Party at the European Medicines Agency. He is also an adviser to various national initiatives, including the Regulatory Science Netwerk Nederland (Regulatory Science Network Netherlands) and the Regie op Registers voor Dure Geneesmiddelen (control of registrations for expensive drugs). In addition, he is a member/chair of various Data Safety and Monitoring Boards.
Roes is a biostatistician with extensive experience in statistical applications, research and education. He is a noted expert in the field of clinical studies, methodology and quality of clinical research. His research mainly concentrates on innovative designs and the analysis of clinical research for rare disorders, a focus that fits well with the more individual patient-oriented treatment.
Radboud university medical center
At Radboud university medical center, Prof. Roes and his team will further expand the contribution of biostatistics to research. The combination of innovative designs for (clinical) research and the increasing possibilities offered by prediction and modelling offer the opportunity to evaluate new treatments and techniques more efficiently and thus bring them to the patient more quickly.
Educating students about statistics and biostatistics is extremely important to a number of programmes. Roes will participate in that effort by focusing on the innovations that are taking place in that field, including design and the increasing availability of large data sets.
About Kit Roes
Kit Roes (Nijmegen, 1961) studied mathematics at Radboud University. After graduation, he went to work as an adviser at Philips. He gained more than 10 years’ experience in quality improvement at various companies and in various settings. He earned a PhD in a related context, focusing on new statistical methods for process control.
Biostatistics became his focus when he began working at Organon. He now has more than 15 years’ experience in clinical and non-clinical research into drug development and he has contributed to the development and registration of new drugs in various therapeutic areas. He has been a professor at UMC Utrecht for the past 10 years, where he initiated and led the EU project Asterix about methodologies for clinical studies of rare diseases.
Prof. Roes is chair of the Methodology work group at the College ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board) and a member of the Biostatistics Working Party at the European Medicines Agency. He is also an adviser to various national initiatives, including the Regulatory Science Netwerk Nederland (Regulatory Science Network Netherlands) and the Regie op Registers voor Dure Geneesmiddelen (control of registrations for expensive drugs). In addition, he is a member/chair of various Data Safety and Monitoring Boards.
Related news items

Researcher Marleen van Gelder cycles to Norway Action for research on preterm births
14 April 2022 A special action by colleague Marleen van Gelder, assistant professor in the Department of Health Evidence. In exactly two months' time, she will be getting on her bicycle to draw attention - and especially money - to research into premature births. read more
Body composition is more important than BMI for renal cancer survival rates
11 January 2022 Body composition is important for survival rates in renal cell cancer. Research from the Radboudumc shows that low muscle quality and low organ fat are associated with poor survival. This involves different stages of renal cancer, ranging from stage I-III to stage IV. read more
Mireille Broeders appointed member of the Dutch Health Council
16 November 2021 Mireille Broeders, professor of Personalized Cancer Screening, has been appointed as a member of the permanent Committee on Population Screening of the Dutch Health Council (Gezondheidsraad). read more
Epidemiology and reporting characteristics of preclinical systematic reviews in PLoS Biology
7 June 2021 Kim Wever, researcher of the department of Health Evidence and an international team published the article 'Epidemiology and reporting characteristics of preclinical systematic reviews' in PLoS Biology. read more
Millions of euros for study of laser treatment for glioblastoma
2 April 2021 A research group from Radboudumc and UMC Utrecht is to investigate laser treatment of a rare brain tumor, glioblastoma. 3.9 million euros has been made available for the research by Zorginstituut Nederland and ZonMw, under the auspices of the Subsidy Scheme for Promising Care. read more